Targetable Mutations in BRAF V600E–Negative Hairy-Cell Leukemia

Abstract excerpt

Patients with hairy-cell leukemia lacking the BRAF V600E mutation often have a BRAF deletion or activating mutation in MAP2K1 , with a poor response to standard therapy. Dabrafenib plus trametinib was active in one patient.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell death mechanisms and regulation
• Share to Chronic Lymphocytic Leukemia Research
• Share to Protein Tyrosine Phosphatases